Cannabidiol inhibits the reward-facilitating effect of morphine: Involvement of 5-HT1A receptors in the dorsal raphe nucleus

Addiction Biology

Volumn 18, Issue 2, 2013, Pages 286-296

  Katsidoni, Vicky ^a   Anagnostou, Ilektra ^a   Panagis, George ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Cannabinoid; cocaine; intracranial self stimulation; morphine; opioids; serotonin

Indexed keywords

CANNABIDIOL; CANNABIS; COCAINE; MORPHINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG MECHANISM; MALE; MEDIAL FOREBRAIN BUNDLE; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; CANNABIDIOL; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; MALE; MEDIAL FOREBRAIN BUNDLE; MICROINJECTIONS; MORPHINE; PIPERAZINES; PYRIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; REWARD; SELF STIMULATION; SENSORY THRESHOLDS; SEROTONIN ANTAGONISTS;

EID: 84874413463     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2012.00483.x     Document Type: Article

References (62)

1. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V, (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852. (Pubitemid 33016156)
2. Campbell KA, Evans G, Gallistel CR, (1985) A microcomputer-based method for physiologically interpretable measurement of the rewarding efficacy of brain stimulation. Physiol Behav 35: 395-403. (Pubitemid 16249644)
3. Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Muller CP, Huston JP, (2005) Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res 1034: 162-171. (Pubitemid 40248528)
4. Carlini EA, Leite JR, Tannhauser M, Berardi AC, (1973) Letter: cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25: 664-665.
5. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS, (2010) Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 21: 353-358.
6. Colpaert FC, Deseure K, Stinus L, Adriaensen H, (2006) High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning. J Pharmacol Exp Ther 316: 892-899. (Pubitemid 43131019)
7. Compton DR, Johnson MR, Melvin LS, Martin BR, (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260: 201-209.
8. Copeland RL, Jr, Pradhan SN, (1988) Effect of morphine on self-stimulation in rats and its modification by chloramphenicol. Pharmacol Biochem Behav 31: 933-935. (Pubitemid 19274306)
9. Coulombe D, Miliaressis E, (1987) Fitting intracranial self-stimulation data with growth models. Behav Neurosci 101: 209-214. (Pubitemid 17077263)
10. Dao JM, McQuown SC, Loughlin SE, Belluzzi JD, Leslie FM, (2011) Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism. Neuropsychopharmacology 36: 1319-1331.
11. Edmonds DE, Gallistel CR, (1974) Parametric analysis of brain stimulation reward in the rat: III. Effect of performance variables on the reward summation function. J Comp Physiol Psychol 87: 876-883.
12. Formukong EA, Evans AT, Evans FJ, (1988) Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 40: 132-134. (Pubitemid 18072269)
13. Gallo A, Lapointe S, Stip E, Potvin S, Rompre PP, (2010) Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behav Brain Res 208: 163-168.
14. Gomes FV, Resstel LB, Guimaraes FS, (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213: 465-473.
15. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW, (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100: 558-559. (Pubitemid 20102368)
16. Harrison AA, Markou A, (2001) Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J Pharmacol Exp Ther 297: 316-325. (Pubitemid 32242592)
17. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
18. Jin X, Semenova S, Yang L, Ardecky R, Sheffler DJ, Dahl R, Conn PJ, Cosford ND, Markou A, (2010) The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology 35: 2021-2036.
19. Johns A, (2001) Psychiatric effects of cannabis. Br J Psychiatry 178: 116-122. (Pubitemid 32158073)
20. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA, (1974) Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172-177.
21. Katsidoni V, Apazoglou K, Panagis G, (2011) Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology 213: 337-354.
22. Kenny PJ, (2007) Brain reward systems and compulsive drug use. Trends Pharmacol Sci 28: 135-141. (Pubitemid 46283593)
23. Kenny PJ, Paterson NE, Boutrel B, Semenova S, Harrison AA, Gasparini F, Koob GF, Skoubis PD, Markou A, (2003) Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci 1003: 415-418. (Pubitemid 38083086)
24. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T, (2010) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13: 861-876.
25. Malone DT, Jongejan D, Taylor DA, (2009) Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)- tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93: 91-96.
26. Mechoulam R, Parker LA, Gallily R, (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S-19S. (Pubitemid 35205041)
27. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO, (2007) Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692. (Pubitemid 47377200)
28. Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D, (1986) The curve-shift paradigm in self-stimulation. Physiol Behav 37: 85-91. (Pubitemid 16121802)
29. Monti JM, (1977) Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology 55: 263-265. (Pubitemid 8243204)
30. Moreira FA, Aguiar DC, Guimaraes FS, (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30: 1466-1471. (Pubitemid 44634958)
31. Morgan CJ, Freeman TP, Schafer GL, Curran HV, (2010a) Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35: 1879-1885.
32. Morgan CJ, Schafer G, Freeman TP, Curran HV, (2010b) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected. Br J Psychiatry 197: 285-290.
33. Morissette MC, Boye SM, (2008) Electrolytic lesions of the habenula attenuate brain stimulation reward. Behav Brain Res 187: 17-26. (Pubitemid 350216185)
34. Murillo-Rodriguez E, Palomero-Rivero M, Millan-Aldaco D, Mechoulam R, Drucker-Colin R, (2011) Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci 88: 504-511.
35. O'Neill KS, Todtenkopf MS, (2010) Using a rate-frequency curve method to assess the rewarding properties of morphine in the intracranial self-stimulation paradigm in rats. J Neurosci Methods 189: 75-79.
36. Panagis G, Vlachou S, Nomikos GG, (2008) Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev 1: 350-374.
37. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R, (2004) Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 175: 360-366. (Pubitemid 39361924)
38. Paxinos G, Watson C, (2007) The Rat Brain in Stereotaxic Coordinates, 6th edn Amsterdam; Boston, MA: Academic Press/Elsevier.
39. Pertwee RG, (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
40. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL, (2009) Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 29: 14764-14769.
41. Rompre PP, Boye S, (1989) Localization of reward-relevant neurons in the pontine tegmentum: a moveable electrode mapping study. Brain Res 496: 295-302. (Pubitemid 19212370)
42. Rompre PP, Miliaressis E, (1985) Pontine and mesencephalic substrates of self-stimulation. Brain Res 359: 246-259. (Pubitemid 16147545)
43. Russo EB, Burnett A, Hall B, Parker KK, (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
44. Schmitz A, Kirsch P, Reuter M, Alexander N, Kozyra E, Kuepper Y, Osinsky R, Hennig J, (2009) The 5-HT1A C(-1019)G polymorphism, personality and electrodermal reactivity in a reward/punishment paradigm. Int J Neuropsychopharmacol 12: 383-392.
45. Schubart CD, Sommer IE, van, Gastel WA, Goetgebuer RL, Kahn RS, Boks MP, (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130: 216-221.
46. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR, (2005) Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30: 2046-2057. (Pubitemid 43093504)
47. Solinas M, Goldberg SR, Piomelli D, (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369-383. (Pubitemid 351670594)
48. Tao R, Karnik M, Ma Z, Auerbach SB, (2003) Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors. Br J Pharmacol 139: 1498-1504. (Pubitemid 37174664)
49. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG, (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623. (Pubitemid 46355558)
50. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA, Jr, (2008) The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64: 982-988.
51. Trujillo-Pisanty I, Hernandez G, Moreau-Debord I, Cossette MP, Conover K, Cheer JF, Shizgal P, (2011) Cannabinoid receptor blockade reduces the opportunity cost at which rats maintain operant performance for rewarding brain stimulation. J Neurosci 31: 5426-5435.
52. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL, (2008) Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
53. Vlachou S, Markou A, (2011) The use of the intracranial self-stimulation in drug abuse research. In:, Olmstead MC, ed. Animal Models of Drug Addiction Neuromethods, 53. pp. 3-56. New York: Humana Press and Springer Science.
54. Vlachou S, Nomikos GG, Panagis G, (2003) WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 141: 215-222. (Pubitemid 36542969)
55. Vlachou S, Stamatopoulou F, Nomikos GG, Panagis G, (2008) Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol 11: 905-923.
56. Wise RA, (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19: 319-340. (Pubitemid 26080832)
57. Wise RA, Rompre PP, (1989) Brain dopamine and reward. Annu Rev Psychol 40: 191-225.
58. Xi ZX, Kiyatkin M, Li X, Peng XQ, Wiggins A, Spiller K, Li J, Gardner EL, (2010) N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 58: 304-313.
59. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL, (2011) Brain cannabinoid CB receptors modulate cocaine's actions in mice. Nat Neurosci 14: 1160-1166.
60. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR, (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159: 122-128.
61. Zuardi AW, Karniol IG, (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16: 141-146. (Pubitemid 13012870)
62. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG, (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250. (Pubitemid 12129400)